Takeda Pharmaceutical Company Limited (NYSE: TAK) Stock Competitors & Peer Comparison

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TEVA trades at $36.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TEVA's P/E ratio is 12.55. In terms of profitability, TAK's ROE is +0.02%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TAK is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TEVA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, HLN has a market cap of 42.7B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while HLN trades at $9.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas HLN's P/E ratio is 18.09. In terms of profitability, TAK's ROE is +0.02%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TAK is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TAK.Check HLN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while VTRS trades at $16.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas VTRS's P/E ratio is 6.44. In terms of profitability, TAK's ROE is +0.02%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VTRS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TAK's ROE is +0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TAK is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ITCI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ELAN trades at $23.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ELAN's P/E ratio is 22.33. In terms of profitability, TAK's ROE is +0.02%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ELAN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TAK's ROE is +0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TAK is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CTLT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while RDY trades at $12.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas RDY's P/E ratio is 20.11. In terms of profitability, TAK's ROE is +0.02%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TAK is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RDY's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while LNTH trades at $100.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas LNTH's P/E ratio is 16.97. In terms of profitability, TAK's ROE is +0.02%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TAK is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check LNTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AMRX trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AMRX's P/E ratio is 20.17. In terms of profitability, TAK's ROE is +0.02%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TAK is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, INDV has a market cap of 4.9B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while INDV trades at $39.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas INDV's P/E ratio is 10.69. In terms of profitability, TAK's ROE is +0.02%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TAK is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INDV's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SUPN trades at $48.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SUPN's P/E ratio is 15.77. In terms of profitability, TAK's ROE is +0.02%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TAK is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SUPN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while RGC trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas RGC's P/E ratio is -383.80. In terms of profitability, TAK's ROE is +0.02%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TAK is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while BHC trades at $6.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas BHC's P/E ratio is 1.66. In terms of profitability, TAK's ROE is +0.02%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TAK is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BHC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TAK's ROE is +0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TAK is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DCPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while HCM trades at $12.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas HCM's P/E ratio is 4.57. In terms of profitability, TAK's ROE is +0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TAK is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HCM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TAK's ROE is +0.02%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TAK is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TAK.Check AVDL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TAK's ROE is +0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TAK is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EMBCV's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TAK's ROE is +0.02%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TAK is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DVAX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PRGO trades at $13.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PRGO's P/E ratio is 5.22. In terms of profitability, TAK's ROE is +0.02%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TAK is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PRGO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ANIP trades at $76.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ANIP's P/E ratio is 9.31. In terms of profitability, TAK's ROE is +0.02%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TAK is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ANIP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TARO's P/E ratio is 30.05. In terms of profitability, TAK's ROE is +0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TAK is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TAK.Check TARO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ETON trades at $58.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ETON's P/E ratio is -840.86. In terms of profitability, TAK's ROE is +0.02%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TAK is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ETON's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while HROW trades at $40.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas HROW's P/E ratio is 444.78. In terms of profitability, TAK's ROE is +0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TAK is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HROW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PAHC trades at $34.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PAHC's P/E ratio is 11.73. In terms of profitability, TAK's ROE is +0.02%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TAK is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PAHC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ALVO trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ALVO's P/E ratio is -11.93. In terms of profitability, TAK's ROE is +0.02%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, TAK is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ALVO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CRON trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CRON's P/E ratio is 29.82. In terms of profitability, TAK's ROE is +0.02%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TAK is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRON's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AMPH has a market cap of 922M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AMPH trades at $20.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AMPH's P/E ratio is 7.14. In terms of profitability, TAK's ROE is +0.02%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TAK is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TAK's ROE is +0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TAK is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PETQ's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, COLL has a market cap of 915.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while COLL trades at $28.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas COLL's P/E ratio is 3.54. In terms of profitability, TAK's ROE is +0.02%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TAK is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check COLL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PCRX has a market cap of 904.7M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PCRX trades at $23.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PCRX's P/E ratio is 8.85. In terms of profitability, TAK's ROE is +0.02%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TAK is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PCRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, IRWD has a market cap of 709.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while IRWD trades at $4.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas IRWD's P/E ratio is 5.53. In terms of profitability, TAK's ROE is +0.02%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check IRWD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, EVO has a market cap of 696.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while EVO trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas EVO's P/E ratio is -2.77. In terms of profitability, TAK's ROE is +0.02%, compared to EVO's ROE of -0.26%. Regarding short-term risk, TAK is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EVO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TAK's ROE is +0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TAK is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check BDSI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, EOLS has a market cap of 537M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while EOLS trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas EOLS's P/E ratio is -25.82. In terms of profitability, TAK's ROE is +0.02%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TAK is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EOLS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AQST has a market cap of 533.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AQST trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AQST's P/E ratio is -6.97. In terms of profitability, TAK's ROE is +0.02%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TAK is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AQST's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TLRY has a market cap of 522.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TLRY trades at $4.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TLRY's P/E ratio is -4.31. In terms of profitability, TAK's ROE is +0.02%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TAK is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLRY's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, KMDA has a market cap of 437.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while KMDA trades at $7.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas KMDA's P/E ratio is 21.66. In terms of profitability, TAK's ROE is +0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TAK is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check KMDA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CGC has a market cap of 424.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CGC trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CGC's P/E ratio is -0.60. In terms of profitability, TAK's ROE is +0.02%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TAK is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TKNO has a market cap of 390.8M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TKNO trades at $7.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TKNO's P/E ratio is -23.52. In terms of profitability, TAK's ROE is +0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TAK is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TKNO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, EMBC has a market cap of 302.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while EMBC trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas EMBC's P/E ratio is 1.96. In terms of profitability, TAK's ROE is +0.02%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, TAK is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EMBC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TAK's ROE is +0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TAK is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ALIM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TAK's ROE is +0.02%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TAK is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LNDC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ORGO has a market cap of 230.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ORGO trades at $1.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ORGO's P/E ratio is 59.67. In terms of profitability, TAK's ROE is +0.02%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TAK is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ORGO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TAK's ROE is +0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TYHT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ACB has a market cap of 227.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ACB trades at $3.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ACB's P/E ratio is -7.51. In terms of profitability, TAK's ROE is +0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TAK is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACB's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SIGA has a market cap of 215.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SIGA trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SIGA's P/E ratio is 11.11. In terms of profitability, TAK's ROE is +0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TAK is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SIGA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CRDL has a market cap of 207.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CRDL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CRDL's P/E ratio is -6.41. In terms of profitability, TAK's ROE is +0.02%, compared to CRDL's ROE of -2.31%. Regarding short-term risk, TAK is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRDL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, DERM has a market cap of 183M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while DERM trades at $6.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas DERM's P/E ratio is -17.97. In terms of profitability, TAK's ROE is +0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TAK is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check DERM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas REPH's P/E ratio is -8.04. In terms of profitability, TAK's ROE is +0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TAK is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check REPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, LFCR has a market cap of 177M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while LFCR trades at $4.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas LFCR's P/E ratio is -4.41. In terms of profitability, TAK's ROE is +0.02%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, TAK is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LFCR's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, OGI has a market cap of 173.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while OGI trades at $1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas OGI's P/E ratio is -4.73. In terms of profitability, TAK's ROE is +0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TAK is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OGI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas THTX's P/E ratio is -28.83. In terms of profitability, TAK's ROE is +0.02%, compared to THTX's ROE of +0.17%. Regarding short-term risk, TAK is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check THTX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TAK's ROE is +0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TAK is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ASRT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CPIX has a market cap of 116.7M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CPIX trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CPIX's P/E ratio is -19.47. In terms of profitability, TAK's ROE is +0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TAK is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPIX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TAK's ROE is +0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TAK is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TAK.Check SCTL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, BGM has a market cap of 110.8M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while BGM trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas BGM's P/E ratio is -1.00. In terms of profitability, TAK's ROE is +0.02%, compared to BGM's ROE of -0.07%. Regarding short-term risk, TAK is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BGM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PROC's P/E ratio is 1.53. In terms of profitability, TAK's ROE is +0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TAK is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PROC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TAK's ROE is +0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TAK is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TAK.Check OPTN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TAK's ROE is +0.02%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TAK is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZOM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TAK's ROE is +0.02%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TAK is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GRVI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ZYBT has a market cap of 75.4M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ZYBT trades at $1.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ZYBT's P/E ratio is -7.23. In terms of profitability, TAK's ROE is +0.02%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TAK is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYBT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TAK's ROE is +0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TAK is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYNE's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TAK's ROE is +0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TAK is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SSIC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TLPH has a market cap of 63.8M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TLPH trades at $1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TLPH's P/E ratio is -3.97. In terms of profitability, TAK's ROE is +0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TAK's ROE is +0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, TAK is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VLNS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TAK's ROE is +0.02%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TAK is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DRRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, INCR has a market cap of 55.1M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while INCR trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas INCR's P/E ratio is -2.15. In terms of profitability, TAK's ROE is +0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TAK is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INCR's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TAK's ROE is +0.02%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, TAK is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check JUPW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CPHI has a market cap of 45.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CPHI trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CPHI's P/E ratio is -1.74. In terms of profitability, TAK's ROE is +0.02%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, TAK is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPHI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas QLI's P/E ratio is -4.92. In terms of profitability, TAK's ROE is +0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TAK is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check QLI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TAK's ROE is +0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TAK is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HEXO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, RMTI has a market cap of 29.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while RMTI trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas RMTI's P/E ratio is -7.06. In terms of profitability, TAK's ROE is +0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TAK is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RMTI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AYTU has a market cap of 25.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AYTU trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AYTU's P/E ratio is -1.24. In terms of profitability, TAK's ROE is +0.02%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TAK is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AYTU's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while TXMD trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas TXMD's P/E ratio is 105.45. In terms of profitability, TAK's ROE is +0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, TAK is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TXMD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TAK's ROE is +0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TAK is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CYTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TAK's ROE is +0.02%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TAK is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TAK.Check EVOK's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, OPTH has a market cap of 15.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while OPTH trades at $4.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas OPTH's P/E ratio is -17.60. In terms of profitability, TAK's ROE is +0.02%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, TAK is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OPTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TAK's ROE is +0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, TAK's ROE is +0.02%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, TAK is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for TAK.Check BFRIW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, COSM has a market cap of 11.9M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas COSM's P/E ratio is -0.30. In terms of profitability, TAK's ROE is +0.02%, compared to COSM's ROE of -0.96%. Regarding short-term risk, TAK is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check COSM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TAK's ROE is +0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TAK is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AGRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TAK's ROE is +0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TAK is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check NLTX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas LCI's P/E ratio is -0.04. In terms of profitability, TAK's ROE is +0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TAK is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LCI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TAK's ROE is +0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TAK is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ADMP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, GELS has a market cap of 5.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while GELS trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas GELS's P/E ratio is -1.16. In terms of profitability, TAK's ROE is +0.02%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TAK is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GELS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, YCBD has a market cap of 5.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while YCBD trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas YCBD's P/E ratio is -1.22. In terms of profitability, TAK's ROE is +0.02%, compared to YCBD's ROE of -0.58%. Regarding short-term risk, TAK is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check YCBD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas MNK's P/E ratio is -0.44. In terms of profitability, TAK's ROE is +0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TAK.Check MNK's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TAK is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check FLGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, UPC has a market cap of 3.6M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while UPC trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas UPC's P/E ratio is -0.70. In terms of profitability, TAK's ROE is +0.02%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check UPC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SBFM trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SBFM's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, TAK is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SBFM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TAK's ROE is +0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TAK is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PLXP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SHPH trades at $4.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SHPH's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, TAK is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SHPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TAK's ROE is +0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TAK is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ATNX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SXTC has a market cap of 2.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SXTC trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SXTC's P/E ratio is 1.51. In terms of profitability, TAK's ROE is +0.02%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, TAK is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SXTC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while SNOA trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas SNOA's P/E ratio is -1.10. In terms of profitability, TAK's ROE is +0.02%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TAK is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SNOA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas PROCW's P/E ratio is N/A. In terms of profitability, TAK's ROE is +0.02%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, TAK is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PROCW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, RDHL has a market cap of 1.8M. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while RDHL trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas RDHL's P/E ratio is 0.12. In terms of profitability, TAK's ROE is +0.02%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, TAK is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RDHL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, TAK's ROE is +0.02%, compared to YCBD-PA's ROE of -0.58%. Regarding short-term risk, TAK is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check YCBD-PA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 56.1B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, TAK is priced at $17.63 on the NYSE, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 12.68, whereas CYTHW's P/E ratio is N/A. In terms of profitability, TAK's ROE is +0.02%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, TAK is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CYTHW's competition here